C-terminal amino acid or Asp-Lys wherein the Lys is attached to the C-terminal amino acid.

- 42. (New) The derivative of claim 41, wherein the lipophilic substituent has 12 to 35 carbon atoms.
- 43. (New) The derivative of claim 42, wherein the lipophilic substituent is tetradecanoyl.
- 44. (New) The derivative of claim 41, wherein the lipophilic substituent is attached to the C-terminal amino acid via a spacer.
- 45. (New) The derivative of claim 44, wherein the spacer is Lys and the lipophilic substituent is -CO(CH<sub>2</sub>)<sub>m</sub>CH<sub>3</sub> wherein m is an integer from 8 to 18 and is attached to the ε-amino group of the spacer.
- 46. (New) The derivative of claim 44, wherein the spacer is Glu-Lys- and the lipophilic substituent is -CO(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub> wherein p is an integer from 10 to 16 and is attached to Glu.

## **REMARKS**

Claims 1-19 have been canceled without prejudice or disclaimer. Claims 20-46 have been added and therefore are pending in the present application.

Claims 20-26 and 34-40 are supported by claims 1, 6 and 9-11 and page 2, line 36 - page 3, line 20 of the specification. Claims 27-32 and 41-46 are supported by claims 1, 6, 13-15 and 17 and page 3, line 36 - page 4, line 19 of the specification. Claim 33 is supported by page 6, lines 5-8 of the specification.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance.

With respect to Applicants' election with traverse of the species D), applicants' basis for traversal of the election of species requirement is that there would be no undue burden on the Examiner to examine all of the alleged species A) through X) of claims 1-19 since in parent application 09/068,822, the Examiner conducted an examination of the same claims (claims 1-19), including a search of the prior art (see March 25, 1999 Office Action).

Applicants also note that no objection to unity of invention was raised at any point of the PCT prosecution by either the International Searching Authority or the

International Preliminary Examining Authority.

Applicants therefore respectfully submit that the election of species requirement is improper and respectfully request reconsideration and withdrawal of this requirement.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: September 6, 2001

Richard W. Bork, Reg. No. 36,459 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

endan Bord

(212) 867-0123

23650
PATENT TRADEMARK OFFICE